Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Accumulated Expenses (2017 - 2025)

Anika Therapeutics (ANIK) has disclosed Other Accumulated Expenses for 14 consecutive years, with $468000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 38.82% to $468000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $468000.0 through Dec 2025, down 38.82% year-over-year, with the annual reading at $468000.0 for FY2025, 38.82% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $468000.0 at Anika Therapeutics, down from $750000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $17.3 million in Q3 2021, with the low at $338000.0 in Q4 2023.
  • Average Other Accumulated Expenses over 5 years is $2.3 million, with a median of $608000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses soared 1581.77% in 2021, then tumbled 97.14% in 2022.
  • Over 5 years, Other Accumulated Expenses stood at $1.1 million in 2021, then crashed by 51.84% to $510000.0 in 2022, then crashed by 33.73% to $338000.0 in 2023, then soared by 126.33% to $765000.0 in 2024, then tumbled by 38.82% to $468000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $468000.0, $750000.0, and $641000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.